Indication
Primary prevention of coronary events in hypercholesterolemic patients without clinically evident coronary heart disease to: Decrease risk of myocardial infarction (MI). Decrease risk of undergoing myocardial revascularization procedure. Decrease risk of cardiovascular mortality. Secondary prevention of cardiac events in patients with clinically evident coronary heart disease to: Decrease risk of myocardial infarction. Decrease risk of undergoing myocardial revascularization procedure. Decrease risk of transient ischemic attach (TIA) and stroke. Slow the progression of coronary atherosclerosis. Adjunctive therapy to diet to diet in patients with primary hyperlipidemia to reduce elevated total cholesterol (Total-C), LDL-C, Apo-B, and triglyceride (TG) levels. Increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type lla and llb). Adjunct to diet for treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Treatment of patients with primary dysberalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Treatment of patients with heterozygous familial hypercholesterolemia (HeFH) in children and adolescents 8 year and older.
